secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001493152-23-027440
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte Q2 revenue $0.5M, net operating loss $8.3M; appoints James Liu interim CFO
--------------------------------------------------------------------------------

- Revenue $0.5M, cost of revenue $0.2M; net operating loss $8.3M vs $8.6M YoY, down $0.3M.
- Cash, equivalents, and marketable securities $17.9M at June 30; avg cash burn below $5M/qtr in 2H 2023.
- R&D expense down 56% YoY to $2.4M; G&A down 36% to $3.5M; S&M down 77% to $0.8M.
- Transplant product launch on track for Q4 early access; MolDX coverage reviews ongoing.
- James Liu (age 28) promoted to Sr. Director, Controller & PAO; appointed interim Principal Financial Officer; salary $200K, target bonus 35%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223027440/0001493152-23-027440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223027440/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer